Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.8K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.9K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chimeric antigen receptor T cell therapy cardiotoxicity: a narrative review.

Cardio-oncology (London, England)·2026
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

[Travel to South Africa by a patient on anti-TNF: Could tuberculosis have been prevented?]

Revue des maladies respiratoires·2025
Same author

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2025

Related Experiment Video

Updated: Mar 23, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Targeting CK2-driven non-oncogene addiction in B-cell tumors.

E Mandato1,2, S Manni1,2, F Zaffino1,2

  • 1Department of Medicine, Hematology Branch, University of Padova, Padova, Italy.

Oncogene
|April 5, 2016
PubMed
Summary

The serine-threonine kinase CK2 is overexpressed in lymphoid tumors, driving cancer growth. Targeting CK2 with inhibitors shows promise for novel combination therapies against these malignancies.

More Related Videos

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.2K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.3K

Related Experiment Videos

Last Updated: Mar 23, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.2K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Lymphoid tumors arise from genetic mutations in oncogenes, but also depend on non-oncogenes for proliferation and survival.
  • The serine-threonine kinase CK2 is increasingly recognized as a key non-oncogene addiction target in various lymphoid malignancies.
  • CK2 is overexpressed and overactive in B-acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphomas.

Purpose of the Study:

  • To review the evidence supporting CK2 as a cancer growth-promoting non-oncogene in lymphoid tumors.
  • To discuss the role of CK2 in supporting oncogene activity, signaling cascades, and stress responses in lymphoid malignancies.
  • To summarize preclinical data on CK2 inhibitors for potential combination therapies.

Main Methods:

  • Literature review of studies on CK2 in lymphoid tumor pathogenesis.
  • Analysis of CK2's role in oncogene cooperation, signaling pathway activation (NF-κB, STAT3, PTEN/PI3K/AKT), and stress response pathways.
  • Evaluation of preclinical data from cell lines and xenograft models using CK2 inhibitors.

Main Results:

  • CK2 supports oncogene activity (e.g., BCR-ABL, c-MYC) and critical signaling cascades (e.g., NF-κB, STAT3, PTEN/PI3K/AKT).
  • CK2 sustains cellular stress responses, including proteotoxic stress, unfolded protein response, and DNA-damage response.
  • Targeting CK2 enhances the cytotoxic effects of conventional and novel agents in lymphoid tumor models.
  • CK2 inhibitors show promise in preclinical studies for combination therapy.

Conclusions:

  • CK2 exhibits characteristics of a cancer growth-promoting non-oncogene in lymphoid tumors.
  • Targeting CK2, particularly with small ATP-competitive inhibitors, offers a promising strategy for novel combination therapies.
  • CK2 inhibitors may provide additional therapeutic options for lymphoid and plasmacellular malignancies.